Silencing strategies for therapy of SOD1-mediated ALS.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Neuroscience Letters

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.neulet.2016.07.059PMID 27507699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adeno‐associated virus–delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model

  2016cited by this paper
• Two superoxide dismutase prion strains transmit amyotrophic lateral sclerosis-like disease.

  2016cited by this paper
• Design of shRNA and miRNA for Delivery to the CNS.

  2016cited by this paper
• Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.

  2016cited by this paper
• SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice

  2015cited by this paper
• MicroRNA Profiling of Atrial Fibrillation in Canines: MiR-206 Modulates Intrinsic Cardiac Autonomic Nerve Remodeling by Regulating SOD1

  2015cited by this paper
• Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling

  2015cited by this paper
• Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1G93A Mice and Nonhuman Primates

  2015cited by this paper
• Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain

  2015cited by this paper
• Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28

  2015cited by this paper
• miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database

  2015cited by this paper
• Improved knockdown from artificial microRNAs in an enhanced miR-155 backbone: a designer's guide to potent multi-target RNAi

  2015cited by this paper
• MicroRNAs: newcomers into the ALS picture.

  2015cited by this paper
• Emerging mechanisms of molecular pathology in ALS.

  2015cited by this paper
• MicroRNA-206: A Potential Circulating Biomarker Candidate for Amyotrophic Lateral Sclerosis

  2014cited by this paper
• Gene Therapy for the Nervous System: Challenges and New Strategies

  2014cited by this paper
• Necroptosis drives motor neuron death in models of both sporadic and familial ALS.

  2014cited by this paper
• Multichannel Compressive Sensing MRI Using Noiselet Encoding

  2014cited by this paper
• Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.

  2014cited by this paper
• Discovery of 1,3,4-oxidiazole scaffold compounds as inhibitors of superoxide dismutase expression.

  2014cited by this paper
• Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS.

  2014cited by this paper
• Therapeutic targeting of microRNAs: current status and future challenges

  2014cited by this paper
• Delayed Disease Onset and Extended Survival in the SOD1G93A Rat Model of Amyotrophic Lateral Sclerosis after Suppression of Mutant SOD1 in the Motor Cortex

  2014cited by this paper
• Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS.

  2013cited by this paper
• Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS

  2013cited by this paper
• Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons

  2013cited by this paper
• The changing scene of amyotrophic lateral sclerosis

  2013cited by this paper
• Amyotrophic lateral sclerosis: Problems and prospects

  2013cited by this paper
• An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

  2013cited by this paper
• Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA

  2013cited by this paper
• Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability.

  2013cited by this paper
• Adeno-associated Virus–mediated Delivery of a Recombinant Single-chain Antibody Against Misfolded Superoxide Dismutase for Treatment of Amyotrophic Lateral Sclerosis

  2013cited by this paper
• Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress

  2013cited by this paper
• State of play in amyotrophic lateral sclerosis genetics

  2013cited by this paper
• Early pathogenesis in the adult‐onset neurodegenerative disease amyotrophic lateral sclerosis

  2012cited by this paper
• Action and reaction: the biological response to siRNA and its delivery vehicles.

  2012cited by this paper
• FUS stimulates microRNA biogenesis by facilitating co‐transcriptional Drosha recruitment

  2012cited by this paper
• A high-throughput screen to identify inhibitors of SOD1 transcription.

  2012cited by this paper
• An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1

  2012cited by this paper
• TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes

  2012cited by this paper
• MicroRNA profiling: approaches and considerations

  2012cited by this paper
• Improved siRNA/shRNA Functionality by Mismatched Duplex

  2011cited by this paper
• Astrocytes from Familial and Sporadic ALS Patients are Toxic to Motor Neurons

  2011cited by this paper
• Polymerase II Promoter Strength Determines Efficacy of microRNA Adapted shRNAs

  2011cited by this paper
• Non-coding RNAs in human disease

  2011cited by this paper
• Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis

  2011cited by this paper
• Genetic therapy for the nervous system.

  2011cited by this paper
• Altered postnatal maturation of electrical properties in spinal motoneurons in a mouse model of amyotrophic lateral sclerosis

  2011cited by this paper
• The connexin26 S17F mouse mutant represents a model for the human hereditary keratitis-ichthyosis-deafness syndrome.

  2011cited by this paper
• Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines

  2011cited by this paper
• Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo

  2011cited by this paper
• ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS

  2010cited by this paper
• MicroRNA control of signal transduction

  2010cited by this paper
• The neurobiology of amyotrophic lateral sclerosis

  2010cited by this paper
• Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS

  2010cited by this paper
• Persistent inward currents in spinal motoneurons: important for normal function but potentially harmful after spinal cord injury and in amyotrophic lateral sclerosis.

  2010cited by this paper
• MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice

  2009cited by this paper
• Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond

  2009cited by this paper
• Nerve Injection of Viral Vectors Efficiently Transfers Transgenes into Motor Neurons and Delivers RNAi Therapy Against ALS

  2009cited by this paper
• MicroRNAs: Target Recognition and Regulatory Functions

  2009cited by this paper
• Early excitability changes in lumbar motoneurons of transgenic SOD1G85R and SOD1G(93A-Low) mice.

  2009cited by this paper
• Prevention of interferon-stimulated gene expression using microRNA-designed hairpins

  2009cited by this paper
• Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic.

  2008cited by this paper
• Neonatal Neuronal Circuitry Shows Hyperexcitable Disturbance in a Mouse Model of the Adult-Onset Neurodegenerative Disease Amyotrophic Lateral Sclerosis

  2008cited by this paper
• Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells.

  2008cited by this paper
• Mitochondrial Dysfunction in SOD1G93A-Bearing Astrocytes Promotes Motor Neuron Degeneration: Prevention by Mitochondrial-Targeted Antioxidants

  2008cited by this paper
• Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi

  2008cited by this paper
• Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons

  2007cited by this paper
• Early electrophysiological abnormalities in lumbar motoneurons in a transgenic mouse model of amyotrophic lateral sclerosis

  2007cited by this paper
• Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis

  2007cited by this paper
• Wild‐type superoxide dismutase acquires binding and toxic properties of ALS‐linked mutant forms through oxidation

  2007cited by this paper
• Combinatorial RNAi: A Winning Strategy for the Race Against Evolving Targets?

  2007cited by this paper
• Non–cell autonomous effect of glia on motor neurons in an embryonic stem cell–based ALS model

  2007cited by this paper
• Expressing short hairpin RNAs in vivo

  2006cited by this paper
• Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia

  2006cited by this paper
• Molecular biology of amyotrophic lateral sclerosis: insights from genetics

  2006cited by this paper
• The neuronal microRNA system

  2006cited by this paper
• Induction of stable RNA interference in mammalian cells

  2006cited by this paper
• Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR‐dependent motor neuron apoptosis

  2006cited by this paper
• Antisense oligonucleotide therapy for neurodegenerative disease.

  2006cited by this paper
• Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.

  2006cited by this paper
• Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

  2006cited by this paper
• Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

  2005cited by this paper
• Increased persistent Na+ current and its effect on excitability in motoneurones cultured from mutant SOD1 mice

  2005cited by this paper
• Virus‐delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis

  2005cited by this paper
• Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS

  2005cited by this paper
• Cell death in amyotrophic lateral sclerosis: interplay between neuronal and glial cells

  2004cited by this paper
• Mammalian RNAi for the masses.

  2003cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

  1994cited by this paper
• The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.

  1993cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

  1993cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

  1993cited by this paper
• Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans.

  1993cited by this paper
• Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

  1978cited by this paper
• Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.

  1978cited by this paper

• Epigenetics in Neurodegenerative Diseases.

  2025cites this paper
• Morpholino–RNA duplex exhibits robust, sustained, and safe steric-block antisense activity by intracerebroventricular and intrathecal injection

  2025influential citation
• Preemptive SOD1 Silencing via Neonatal Intramuscular AAV Therapy Modifies Disease Trajectory in an ALS Mouse Model

  2025influential citation
• Genetic therapies for neurological diseases

  2025cites this paper
• Boldine as a neuroprotective agent against motor neuron degeneration in models of amyotrophic lateral sclerosis

  2025cites this paper
• Which One Would You Choose?—Investigation of Widely Used Housekeeping Genes and Proteins in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis

  2025cites this paper
• Muscle Matters: Transforming Amyotrophic Lateral Sclerosis Diagnostics with Next-Gen Biosensors and Smart Detection.

  2025cites this paper
• Skeletal myotubes expressing ALS mutant SOD1 induce pathogenic changes, impair mitochondrial axonal transport, and trigger motoneuron death

  2024cites this paper
• Skeletal myotubes expressing ALS mutant SOD1 induce pathogenic changes, impair mitochondrial axonal transport, and trigger motoneuron death

  2024cites this paper
• Advancements in Pharmacological Interventions and Novel Therapeutic Approaches for Amyotrophic Lateral Sclerosis

  2024cites this paper
• In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification

  2024cites this paper
• Mature iPSC-derived astrocytes of an ALS/FTD patient carrying the TDP43 A90V mutation display a mild reactive state and release polyP toxic to motoneurons

  2023cites this paper
• Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis

  2023cites this paper
• Analysis of proteome-wide degradation dynamics in ALS SOD1 iPSC-derived patient neurons reveals disrupted VCP homeostasis

  2023cites this paper
• Potential of oligonucleotide- and protein/peptide-based therapeutics in the management of toxicant/stressor-induced diseases

  2023cites this paper
• Unveiling promising inhibitors of superoxide dismutase 1 (SOD1) for therapeutic interventions.

  2023cites this paper
• Advances in the Structure of GGGGCC Repeat RNA Sequence and Its Interaction with Small Molecules and Protein Partners

  2023cites this paper
• Protective effects of intrathecal injection of AAV9-RabGGTB-GFP+ in SOD1G93A mice

  2023cites this paper
• Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders.

  2022cites this paper
• Behavioral and Cognitive Phenotypes of Patients With Amyotrophic Lateral Sclerosis Carrying SOD1 Variants

  2022cites this paper
• Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial

  2022cites this paper
• The Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis

  2022cites this paper
• Overexpression of ferroptosis defense enzyme Gpx4 retards motor neuron disease of SOD1G93A mice

  2021cites this paper
• Potential underlying genetic associations between keratoconus and diabetes mellitus

  2021cites this paper
• Ligand-Induced Stabilization of the Native Human Superoxide Dismutase 1.

  2021cites this paper
• Premature termination codons in SOD1 causing Amyotrophic Lateral Sclerosis are predicted to escape the nonsense-mediated mRNA decay

  2020cites this paper
• Kinetic variability in seeded formation of ALS-linked SOD1 fibrils across multiple generations.

  2020cites this paper
• Disease-modifying therapies in amyotrophic lateral sclerosis.

  2020cites this paper
• The Timing and Extent of Motor Neuron Vulnerability in ALS Correlates with Accumulation of Misfolded SOD1 Protein in the Cortex and in the Spinal Cord

  2020cites this paper
• Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS)

  2020influential citation
• Circulating MicroRNAs as Diagnostic Biomarkers for Motor Neuron Disease

  2020cites this paper
• Intralingual Administration of AAVrh10-miR SOD1 Improves Respiratory But Not Swallowing Function in a Superoxide Dismutase-1 Mouse Model of Amyotrophic Lateral Sclerosis

  2020influential citation
• Downregulated miR-18b-5p triggers apoptosis by inhibition of calcium signaling and neuronal cell differentiation in transgenic SOD1 (G93A) mice and SOD1 (G17S and G86S) ALS patients

  2020cites this paper
• Multifaceted Genes in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia

  2020cites this paper
• Effects of Flax Lignans on Spatial Learning and Memory in Diabetic Encephalopathy Mice and Its Mechanism*

  2020cites this paper
• BDNF-overexpressing human umbilical cord mesenchymal stem cell-derived motor neurons improve motor function and prolong survival in amyotrophic lateral sclerosis mice

  2020cites this paper
• SOD1-targeting therapies for neurodegenerative diseases: a review of current findings and future potential

  2020cites this paper
• SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis.

  2019cites this paper
• Novel Aspects on Motor Neuron Disease: The Recent Genetic Studies on ALS

  2019cites this paper
• Lentivirus vector mediated SOD1 gene silencing targets the PI3K/AKT signaling pathway to protect dopaminergic neurons from oxidative stress in the substantia nigra of Parkinson’s disease rats

  2019influential citation
• Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS

  2019cites this paper
• An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis.

  2019cites this paper
• An in vitro model for studying CNS white matter: functional properties and experimental approaches

  2019cites this paper
• Neuroprotection in Amyotrophic Lateral Sclerosis

  2019cites this paper
• Thrombin and the Coag-Inflammatory Nexus in Neurotrauma, ALS, and Other Neurodegenerative Disorders

  2019cites this paper
• 50-Hz magnetic field impairs the expression of iron-related genes in the in vitro SOD1G93A model of amyotrophic lateral sclerosis

  2019cites this paper
• MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis

  2018cites this paper
• Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases

  2018cites this paper
• Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques

  2018cites this paper
• Anti-Inflammatory Effect of Gamisoyo-San in an Animal Model of Amyotrophic Lateral Sclerosis

  2018cites this paper
• Stress Granules and ALS: A Case of Causation or Correlation?

  2018cites this paper
• RNA Metabolism in Neurodegenerative Diseases

  2018cites this paper
• Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis

  2018cites this paper
• Implications of PI3K/AKT/PTEN Signaling on Superoxide Dismutases Expression and in the Pathogenesis of Alzheimer’s Disease

  2018cites this paper
• Transplantation of Neural Progenitor Cells Expressing Glial Cell Line‐Derived Neurotrophic Factor into the Motor Cortex as a Strategy to Treat Amyotrophic Lateral Sclerosis

  2018cites this paper
• Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody

  2018cites this paper
• Dexmedetomidine alleviates lipopolysaccharide-induced lung injury in Wistar rats

  2017cites this paper
• Genome-wide circulating microRNA expression profiling reveals potential biomarkers for amyotrophic lateral sclerosis.

  2017cites this paper
• ALS: new molecular mechanisms and emerging therapeutic targets.

  2017cites this paper
• Iron mediated toxicity and programmed cell death: A review and a re-examination of existing paradigms.

  2017cites this paper
• Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis

  2017cites this paper
• Novel PEI/Poly-γ-Gutamic Acid Nanoparticles for High Efficient siRNA and Plasmid DNA Co-Delivery

  2017cites this paper
• Identification and characterization of RNA aptamers: A long aptamer blocks the AMPA receptor and a short aptamer blocks both AMPA and kainate receptors

  2017influential citation
• Modelling amyotrophic lateral sclerosis: progress and possibilities

  2017cites this paper
• Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: Converging roads to therapeutic development.

  2017cites this paper
• Nuclear export of misfolded SOD1 mediated by a normally buried NES-like sequence reduces proteotoxicity in the nucleus

  2017cites this paper
• The evolving genetic risk for sporadic ALS

  2017cites this paper